Cancer is an abnormal growth of cells in the body, also known as malignancy. It has the potential to replicate itself rapidly and invade into other body parts also. There are numerous types of cancer present. Dendritic cells (part of neuron) plays an important role in inducing anti-tumor activity. Hence, various strategies are being developed to treat cancer with the help of dendritic cell. For generation of dendritic vaccine, dendritic cells are cultured alongside the cancer cells. The vaccine, when induced into body stimulates the immune system to attack cancer cells.
Global Dendritic Cell and Tumor Cell Vaccines Market Drivers
Increase in research and development activities related to dendritic cell and tumor cell based vaccines are expected to accelerate the global dendritic cell and tumor cell vaccines market growth. For instance, in March 2015, Rockefeller University and Memorial Sloan Kettering Cancer Center conducted a phase II study of autologous dendritic cell vaccines (DC/PC3). It is being used as an immunotherapy in the prostate cancer. The vaccine was developed by patient’s own cells.
Furthermore, in April 2016, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) S.r.l., began its study on autologous dendritic cells loaded with autologous tumor homogenate in combination with the drug IL-2. It is being used for the treatment of patients with stage IV colorectal cancer. The purpose of study is to evaluate the consistency of the response of immune cells after completion of the treatment. Currently, the study is in its second phase of clinical trials. Hence, such research and development activities of dendritic cell and tumor cell vaccines are expected to impel the global dendritic cell and tumor cell vaccines market growth.
Approvals of vaccines by regulatory bodies are expected to drive the global dendritic cell and tumor cell vaccines market growth. For instance, in June 2018, Northwest BioTherapeutics received U.S. Food & Drug Administration (FDA) approval for its dendritic cell vaccine, DCVax – L. It is being used for the treatment of cancer type, glioblastoma. Its clinical study revealed that many patients survived for over one and half years after the vaccination. Hence, such approved vaccines based on dendritic cell are expected to drive the global dendritic cell and tumor cell vaccine market growth.
Global Dendritic Cell and Tumor Cell Vaccines Market Regional Analysis
North America is expected to be a dominant region in the global dendritic cell and tumor cell vaccines market, with increasing prevalence of cancer in the region. According to National Institutes of Health (NIH) data, in 2018, around 609,640 people died due to cancer and incidence rate was 439.2 per 100,000 men and women per year. The most occurring cancer type are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, and kidney and renal pelvis cancer. Hence, the higher prevalence of cancer may lead to higher demand for dendritic cell and tumor cell vaccines and thereby, expected to propel the global dendritic cell and tumor cell vaccine market growth.
Global Dendritic Cell and Tumor Cell Vaccines Market Restraints
Withdrawal of dendritic cell and tumor cell vaccines from its clinical trials are expected to hamper the global dendritic cell and tumor cell vaccines clinical progress. For instance, in March 2016, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, conducted its clinical trial for dendritic cell vaccine with radiotherapy. It was being studied for the treatment of renal cancer. However, it got withdrawn in its second phase of clinical trial (reason unspecified). Hence, this factor may have a negative impact on the global dendritic and tumor cell vaccine market growth.
Global Dendritic Cell and Tumor Cell Vaccines Market Key Players
Some of the major players operating in the global dendritic cell and tumor cell vaccines market include, JW CreaGene, Miltenyi Biotec, GlaxoSmithKline plc, NorthWest BioTherapeutics, ImmunoCellular Therapeutics, Ltd., EnoChian Biosciences, Medigene AG, DC Prime, Tella Incorporation, and CiMaas
Global Dendritic Cell and Tumor Cell Vaccines Market Taxonomy
- CD 4
- CD 8
- T-helper cell
- Glioblastoma Cancer
- Prostate Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Renal Cancer
- Lung Cancer
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East